Sclerotherapy and Candida Antigen in Treatment of Common Warts
ConditionCommon Wart
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorSohag University
About this trial
This study aims to evaluate the efficacy and safety of intralesional injections of candida antigen, polidocanol sclerotherapy and combined candida antigen with polidocanol in treatment of patients with common warts.
Eligibility criteria
Qualifiers
Age group: >18years.
Confirmed diagnosis by clinical and dermoscopic examination of common wart will be made.
Disqualifiers
Patients who receive any treatment for wart in the last month before the study.
Patients with history of renal or liver disease.
Patients with any evidence of bleeding diathesis, vaso-occulusive or thrombo-embolic disorders.
Pregnant and lactating females.
Trial design
Treatments tested in this trial
- polidacanol 3%
- candida antigen
Treatment groups
75 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov